Title | Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MTeresa, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N, Nos G, Tabbo F, Frenkel F, Ghione P, Tsiper M, Almog N, Fowler N, Melnick AM, Leonard JP, Inghirami G, Cerchietti L |
Journal | Cancer Discov |
Volume | 11 |
Issue | 6 |
Pagination | 1468-1489 |
Date Published | 2021 Jun |
ISSN | 2159-8290 |
Abstract | Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Transcriptomic and genetic characterization of DLBCL has increased the understanding of its intrinsic pathogenesis and provided potential therapeutic targets. However, the role of the microenvironment in DLBCL biology remains less understood. Here, we performed a transcriptomic analysis of the microenvironment of 4,655 DLBCLs from multiple independent cohorts and described four major lymphoma microenvironment categories that associate with distinct biological aberrations and clinical behavior. We also found evidence of genetic and epigenetic mechanisms deployed by cancer cells to evade microenvironmental constraints of lymphoma growth, supporting the rationale for implementing DNA hypomethylating agents in selected patients with DLBCL. In addition, our work uncovered new therapeutic vulnerabilities in the biochemical composition of the extracellular matrix that were exploited to decrease DLBCL proliferation in preclinical models. This novel classification provides a road map for the biological characterization and therapeutic exploitation of the DLBCL microenvironment. SIGNIFICANCE: In a translational relevant transcriptomic-based classification, we characterized the microenvironment as a critical component of the B-cell lymphoma biology and associated it with the DLBCL clinical behavior establishing a novel opportunity for targeting therapies.. |
DOI | 10.1158/2159-8290.CD-20-0839 |
Alternate Journal | Cancer Discov |
PubMed ID | 33541860 |
PubMed Central ID | PMC8178179 |
Grant List | R01 CA242069 / CA / NCI NIH HHS / United States |
Related Faculty:
Giorgio Inghirami, M.D.